<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826432</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002507-18</org_study_id>
    <secondary_id>2019/2955</secondary_id>
    <nct_id>NCT04826432</nct_id>
  </id_info>
  <brief_title>Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis</brief_title>
  <acronym>PASIREOCHIP</acronym>
  <official_title>Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative&#xD;
      digestive leakage after CRS plus HIPEC compared to placebo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Single-blinded, multicentric, placebo controlled phase II comparative trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative digestive leakage</measure>
    <time_frame>97 days</time_frame>
    <description>The rate of clinically relevant (NCI CTCAE v5 ≥ grade 3) postoperative digestive leakage at 97 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">217</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide 0.9 MG/ML</intervention_name>
    <description>0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours</description>
    <arm_group_label>Pasireotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline water</intervention_name>
    <description>0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged between 18 years and 75 years included&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) Performance Status ≤ 2&#xD;
&#xD;
          -  Primary (pseudomyxoma peritonei, peritoneal mesothelioma) or Secondary (colorectal or&#xD;
             ovarian) peritoneal malignancies&#xD;
&#xD;
          -  Curative intent resection obtained by a complete resection according to the&#xD;
             Completeness of Cytoreduction score (CC) (CC 0-1) followed by HIPEC Different&#xD;
             intraperitoneal drug administration modalities such as neoadjuvant systemic plus&#xD;
             simultaneous intraperitoneal and intravenous chemotherapy (NIPS) or pressurized&#xD;
             intra-peritoneal aerosol chemotherapy (PIPAC) does not represent exclusion criteria.&#xD;
&#xD;
          -  Absence of extra-peritoneal metastatic disease or limited hepatic or lung metastases&#xD;
             easily amenable to curative-intent resection or ablation&#xD;
&#xD;
          -  Intraoperative Peritoneal Cancer Index (PCI score) ≥ 10&#xD;
&#xD;
          -  Visceral resection with at least one digestive anastomosis with or without loop&#xD;
             ileostomy or pancreatic or biliary resection.&#xD;
&#xD;
          -  Negative serum pregnancy test for women of childbearing potential within 7 days prior&#xD;
             to therapy&#xD;
&#xD;
          -  Sexually active women of childbearing potential must agree to use a highly effective&#xD;
             method of contraception or to abstain from sexual activity during the study and for 3&#xD;
             months after the last study treatment administration. Sexually active males patients&#xD;
             must agree to use condom or to abstain from sexual activity during the study and for 3&#xD;
             months after the last study treatment administration. Also, it is recommended their&#xD;
             women of childbearing potential partner use a highly effective method of contraception&#xD;
             during the same period.&#xD;
&#xD;
          -  Patient should understand, sign, and date the written informed consent form prior to&#xD;
             any protocol-specific procedures performed. Patient should be able and willing to&#xD;
             comply with study visits and procedures as per protocol.&#xD;
&#xD;
          -  Patients must be affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macroscopically incomplete surgical resection (CC 2)&#xD;
&#xD;
          -  Standard contraindications to pasireotide:&#xD;
&#xD;
               1. patients with uncontrolled diabetes mellitus or a fasting plasma glucose &gt;&#xD;
                  250mg/dl (14 mMol/L)&#xD;
&#xD;
               2. patients who have congestive heart failure (NYHA Class III or IV), unstable&#xD;
                  angina, sustained ventricular tachycardia, ventricular fibrillation, clinically&#xD;
                  significant bradycardia including a corrected QT (QTc) interval longer than 450&#xD;
                  msec, advanced heart block or a history of acute myocardial infarction within the&#xD;
                  six months preceding enrollment&#xD;
&#xD;
               3. patients with liver disease such as severe hepatic impairment (Child Pugh C),&#xD;
                  chronic active hepatitis or chronic persistent hepatitis with abnormal&#xD;
                  coagulation (INR&gt;1.5).&#xD;
&#xD;
               4. patients with the presence of active or suspected acute or chronic uncontrolled&#xD;
                  infection&#xD;
&#xD;
               5. hypersensitivity to somatostatin analogues or any component of pasireotide&#xD;
                  formulations&#xD;
&#xD;
               6. patients with uncontrolled hypothyroidism&#xD;
&#xD;
          -  Patients participating or who have participated to another study evaluating the effect&#xD;
             of a new drug other than pasireotide within 1 month prior to dosing&#xD;
&#xD;
          -  Patient who have already participated to this study (a patient can only be included&#xD;
             once in the study)&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will be unable to complete the entire study.&#xD;
&#xD;
          -  Women who are pregnant or likely to be so, or who are breastfeeding&#xD;
&#xD;
          -  Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maximiliano Gelli, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>maximiliano.gelli@gustaveroussy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximiliano Gelli, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>maximiliano.gelli@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thibaud Motreff</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>thibaud.motreff@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

